Aaron Koenig, Michael Lewis, Jeff Wald, Sigui Li, Mustafa Varoglu, Jing Dai, . . . Mike Quirk. (2024). Dalzanemdor (SAGE‐718), a novel, investigational N‐methyl‐D‐aspartate receptor positive allosteric modulator: Safety, tolerability, and clinical pharmacology in randomized dose‐finding studies in healthy participants and an open‐label study in participants with Huntington's disease. Wiley.
Chicago Style (17th ed.) CitationAaron Koenig, et al. Dalzanemdor (SAGE‐718), a Novel, Investigational N‐methyl‐D‐aspartate Receptor Positive Allosteric Modulator: Safety, Tolerability, and Clinical Pharmacology in Randomized Dose‐finding Studies in Healthy Participants and an Open‐label Study in Participants with Huntington's Disease. Wiley, 2024.
MLA (9th ed.) CitationAaron Koenig, et al. Dalzanemdor (SAGE‐718), a Novel, Investigational N‐methyl‐D‐aspartate Receptor Positive Allosteric Modulator: Safety, Tolerability, and Clinical Pharmacology in Randomized Dose‐finding Studies in Healthy Participants and an Open‐label Study in Participants with Huntington's Disease. Wiley, 2024.